The decision to use GLP-1 receptor agonists should be based on their licensed indications (diabetes or obesity management) rather than cholesterol lowering alone, with lipid improvements considered a beneficial additional effect within a comprehensive cardiovascular risk reduction strategy
C., & Wadden, T
doi: 10.5314/wjd.v9.i1.1 534 BrodmannTEndoAGueimondeMVinderolaGKneifelWde VosWMet al
Activating both pathways together produces a more pronounced effect on appetite suppression, fat loss, and metabolic efficiency than either pathway alone which is why clinical trial data consistently shows tirzepatide producing greater average weight loss than single-receptor GLP-1 medications
Why the Empty Stomach and Water-Only Rules Matter The strict administration requirements for Rybelsus are rooted in the unique pharmacokinetic properties of oral semaglutide and the physiological processes governing drug absorption in the upper gastrointestinal tract
Furthermore, the requirement for patients to have an available weight measurement on the index date and after 1 year of follow-up and to be persistent on therapy for 1 year may have introduced potential selection bias in favor of patients who are more actively managed and/or for whom treatment is effective